Mainz Biomed (NASDAQ:MYNZ – Get Free Report)’s stock price was down 5.7% on Monday . The stock traded as low as $0.21 and last traded at $0.23. Approximately 3,189,528 shares were traded during trading, an increase of 158% from the average daily volume of 1,236,763 shares. The stock had previously closed at $0.24.
Mainz Biomed Stock Performance
The stock’s fifty day simple moving average is $0.27 and its 200-day simple moving average is $0.42.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Articles
- Five stocks we like better than Mainz Biomed
- What is the Shanghai Stock Exchange Composite Index?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- 10 Best Airline Stocks to Buy
- Applied Materials Market Capitulates: Now is the Time to Buy
- How Can Investors Benefit From After-Hours Trading
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
